How has Agios Pharmaceuticals's operating lease liabilities changed year-over-year?

Agios Pharmaceuticals's operating lease liabilities decreased by 10.2% year-over-year, from -$4.05M to -$4.46M.

What is the long-term trend for Agios Pharmaceuticals's operating lease liabilities?

Over 4 years (2021 to 2025), Agios Pharmaceuticals's operating lease liabilities has grown at a 22.2% compound annual growth rate (CAGR), from -$7.53M to -$16.78M.

Agios Pharmaceuticals AGIO Operating lease liabilities

Operating lease liabilities at other companies

Disc MedicineIRON

——

PrecigenPGEN

——

PVL

Palvella TherapeuticsPVLA

——

Aurinia PharmaceuticalsAUPH

——

BridgeBio PharmaBBIO

——

Arrowhead ResearchARWR

——

Other financials

Income statement

See full

Revenue$20.7M+138%

Gross profit$19.4M+154%

Operating income-$110.0M-3.2%

Net income-$99.1M-11.0%

EPS (diluted)-$1.69-9.0%

Balance sheet

See full

Cash & equivalents$113.6M+43.9%

Total debt$35.7M-32.5%

Total equity$1.1B-24.4%

Total assets$1.2B-23.8%

Cash flow

See full

Operating cash flow-$118.9M-6.7%

CapEx$769.0K+0.4%

Free cash flow-$119.7M-6.6%

Valuation

See full

Market cap$2.16B+18.1%

Profitability

See full

Gross margin90%+2.5pp

Operating margin-720%-204pp

Net margin-639.8%—

FCF margin-582.5%-185pp

Returns & leverage

See full

Return on equity-32.8%—

Debt / equity0×0.0×

Current ratio14.2×-4.3×

Where this comes from

Reported directly by Agios Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Agios Pharmaceuticals's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Agios Pharmaceuticals's operating lease liabilities?: Agios Pharmaceuticals (AGIO) reported operating lease liabilities of -$4.46M in Q1 2026.
How has Agios Pharmaceuticals's operating lease liabilities changed year-over-year?: Agios Pharmaceuticals's operating lease liabilities decreased by 10.2% year-over-year, from -$4.05M to -$4.46M.
What is the long-term trend for Agios Pharmaceuticals's operating lease liabilities?: Over 4 years (2021 to 2025), Agios Pharmaceuticals's operating lease liabilities has grown at a 22.2% compound annual growth rate (CAGR), from -$7.53M to -$16.78M.